ArticleSubstance use & misuse2021
"The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
Article in Substance use & misuse, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- "It was good because they have a relationship with us": A qualitative study on low-threshold buprenorphine treatment at syringe services programs.Journal of substance use and addiction treatment · 2026Trial
- Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants.Addiction science & clinical practice · 2026Trial
- Concurrent Use of Extra-Medical Medication for Opioid Use Disorder Among Adults Prescribed Methadone or Buprenorphine: A Cohort Study of Urban Adults Who Have Injected Drugs.Drug and alcohol review · 2026Article
- Low-threshold Buprenorphine: Proposing the Ideal Service Model to Engage People With Severe Opioid Use Disorder.Journal of addiction medicine · 2026Article
- MiBUP: A pilot randomized controlled trial of low-dose initiation of buprenorphine for opioid use disorder: Design and rationale.Contemporary clinical trials communications · 2026Article
- An Analysis of Treatment Preferences of Patients With Opioid Use Disorders: Findings From A Tertiary Drug Dependence Treatment Center in India.Addiction & health · 2026Article
- Pain Neuroscience Education on Reducing Opioid Dependency in African American and Caucasian Populations: A Narrative Review.Journal of clinical medicine · 2025Review
- Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug and alcohol dependence · 2025Article
- Low-dose buprenorphine initiation and treatment continuation among hospitalized patients with opioid dependence: A retrospective cohort study.Journal of substance use and addiction treatment · 2024Article
- Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.Harm reduction journal · 2023Article
- Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder.JAMA health forum · 2023Observational
- Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.Journal of substance use and addiction treatment · 2023Article
- Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021.Drug and alcohol dependence reports · 2023Article
- Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.Journal of substance abuse treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPeople may overcome barriers to professional buprenorphine treatment by using non-prescribed buprenorphine (NPB) to manage opioid use disorder (OUD). Little is known about how people perceive NPB differently than formal treatment. This qualitative study investigated how and why people use NPB as an alternative to formal treatment.
methodsIn-depth, semi-structured interviews were conducted with participants of harm reduction agencies (
resultsThree main factors drove decisions about prescribed and non-prescribed buprenorphine use: 1) autonomy; 2) treatment goals; and 3) negative early experiences with NPB. An overarching theme from our analysis was that participants valued autonomy in seeking to control their substance use. NPB was a valuable tool toward this goal and professional OUD treatment could impede autonomy. Participants mostly used NPB to "self-manage" OUD symptoms. Many participants had concerns about long-term buprenorphine treatment and instead used NPB over short periods of time. Several participants also reported negative experiences with NPB, including symptoms of withdrawal, which then deterred them from seeking out professional treatment.
conclusionsThese results support prior studies showing that people use NPB to self-manage withdrawal symptoms and to reduce use of illicit opioids. Despite these benefits, participants focused on short-term goals and negative consequences were common. Increasing buprenorphine treatment engagement may require attention to patients' sense of autonomy, and also assurance that long-term treatment is safe, effective, and reliably accessible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.